125 related articles for article (PubMed ID: 10965500)
1. Oestrogen receptor function at classical and alternative response elements.
Kushner PJ; Agard D; Feng WJ; Lopez G; Schiau A; Uht R; Webb P; Greene G
Novartis Found Symp; 2000; 230():20-6; discussion 27-40. PubMed ID: 10965500
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor pathways to AP-1.
Kushner PJ; Agard DA; Greene GL; Scanlan TS; Shiau AK; Uht RM; Webb P
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):311-7. PubMed ID: 11162939
[TBL] [Abstract][Full Text] [Related]
3. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity.
Fan JD; Wagner BL; McDonnell DP
Mol Endocrinol; 1996 Dec; 10(12):1605-16. PubMed ID: 8961270
[TBL] [Abstract][Full Text] [Related]
4. Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF).
Klinge CM
J Steroid Biochem Mol Biol; 1999 Nov; 71(1-2):1-19. PubMed ID: 10619353
[TBL] [Abstract][Full Text] [Related]
5. Comparison of tamoxifen ligands on estrogen receptor interaction with estrogen response elements.
Klinge CM; Studinski-Jones AL; Kulakosky PC; Bambara RA; Hilf R
Mol Cell Endocrinol; 1998 Aug; 143(1-2):79-90. PubMed ID: 9806352
[TBL] [Abstract][Full Text] [Related]
6. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site.
Petz LN; Ziegler YS; Schultz JR; Nardulli AM
Mol Endocrinol; 2004 Mar; 18(3):521-32. PubMed ID: 14684847
[TBL] [Abstract][Full Text] [Related]
7. The aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT) heterodimer interacts with naturally occurring estrogen response elements.
Klinge CM; Bowers JL; Kulakosky PC; Kamboj KK; Swanson HI
Mol Cell Endocrinol; 1999 Nov; 157(1-2):105-19. PubMed ID: 10619402
[TBL] [Abstract][Full Text] [Related]
8. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
[TBL] [Abstract][Full Text] [Related]
9. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.
Webb P; Nguyen P; Valentine C; Lopez GN; Kwok GR; McInerney E; Katzenellenbogen BS; Enmark E; Gustafsson JA; Nilsson S; Kushner PJ
Mol Endocrinol; 1999 Oct; 13(10):1672-85. PubMed ID: 10517669
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells.
Petz LN; Ziegler YS; Loven MA; Nardulli AM
Endocrinology; 2002 Dec; 143(12):4583-91. PubMed ID: 12446585
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
12. Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators.
Lopez GN; Webb P; Shinsako JH; Baxter JD; Greene GL; Kushner PJ
Mol Endocrinol; 1999 Jun; 13(6):897-909. PubMed ID: 10379889
[TBL] [Abstract][Full Text] [Related]
13. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators.
An J; Ribeiro RC; Webb P; Gustafsson JA; Kushner PJ; Baxter JD; Leitman DC
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15161-6. PubMed ID: 10611355
[TBL] [Abstract][Full Text] [Related]
14. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
15. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.
Klinge CM; Jernigan SC; Mattingly KA; Risinger KE; Zhang J
J Mol Endocrinol; 2004 Oct; 33(2):387-410. PubMed ID: 15525597
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen agonism and estrogen antagonism of c-fos gene promoter activity through non-consensus-responsive elements in MC3T3-E1 osteoblasts.
Ishibashi O; Yamagishi T; Hanada K; Kawashima H
Biochem Biophys Res Commun; 2001 Dec; 289(3):705-11. PubMed ID: 11726205
[TBL] [Abstract][Full Text] [Related]
17. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways.
Safe S; Kim K
J Mol Endocrinol; 2008 Nov; 41(5):263-75. PubMed ID: 18772268
[TBL] [Abstract][Full Text] [Related]
18. Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site.
Weatherman RV; Carroll DC; Scanlan TS
Bioorg Med Chem Lett; 2001 Dec; 11(24):3129-31. PubMed ID: 11720858
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element.
Uht RM; Anderson CM; Webb P; Kushner PJ
Endocrinology; 1997 Jul; 138(7):2900-8. PubMed ID: 9202234
[TBL] [Abstract][Full Text] [Related]
20. Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1.
Cheung E; Acevedo ML; Cole PA; Kraus WL
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):559-64. PubMed ID: 15642950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
